Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,078.40
(
-0.48%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
99.14
(
2.50%
)
Bitcoin
77,870.19
(
-0.47%
)
News Focus
News Focus
Post# of 6280
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Prudent Capitalist

Send PM Follow Ignore
Followers 142
Posts 20057
Boards Moderated 9
Alias Born 05/28/2009

Prudent Capitalist

Re: sts66 post# 6081

Wednesday, 09/03/2014 9:37:36 AM

Wednesday, September 03, 2014 9:37:36 AM

Post# of 6280
There is no such issue here with AVNR. The critical fact here with AVNR is that there are no generics. That is what the victory in the 5 legal actions was all about. The court ruled that AVNR's patent is valid and exclusive, and there will be no competition from any generic form of Nuedexta and related compounds until late 2026.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today